Clearmind Biomedical has announced that it recently signed an exclusive US distribution agreement with Sutter Medical Technologies USA for the Neuroblade multi-function neuro-endoscope system—a US Food and Drug Administration (FDA) 510(k)-cleared device engineered to advance the treatment of complex neurosurgical conditions like intracranial haemorrhage (ICH).
In addition, Neuroblade will be featured at the upcoming Congress of Neurological Surgeons (CNS) annual meeting (11–15 October, Los Angeles, USA).
The Neuroblade system is claimed by Clearmind to address an unmet need in ICH treatment by providing neurosurgeons with “a new paradigm” for haemorrhage evacuation, offering a single, minimally invasive platform that integrates visualisation, illumination, irrigation, suction, coagulation, and powered debridement.
This combination is designed to streamline surgical workflow, reduce instrument exchanges, and improve surgical precision—ultimately enhancing patient outcomes and the potential for recovery—according to the company.
“Clearmind’s mission has always been to simplify and advance the surgical treatment of haemorrhagic stroke, so patients not only survive but return to independent lives,” said J Dustin Duckett, Clearmind vice president and general manager, Americas. “By partnering with Sutter Medical, we can accelerate adoption of the Neuroblade across leading stroke and neurosurgical centres in the USA, giving surgeons the tools they need to treat ICH more effectively.”
Under the agreement, Sutter Medical—a company globally recognised for its non-stick bipolar forceps and radiofrequency systems—will serve as the exclusive distributor of the Neuroblade in the USA. With its established commercial infrastructure and trusted surgeon relationships, Sutter Medical will expand access to this next-generation technology.
“We are proud to add the Neuroblade to our US portfolio,” commented Brent Lacy, Sutter Medical vice president. “Its unique combination of minimally invasive access and integrated functionality aligns perfectly with our mission to provide neurosurgeons with tools that improve surgical workflow and precision, and enhance patient outcomes.”
